Your browser doesn't support javascript.
loading
Recent advances in the treatment of gout with NLRP3 inflammasome inhibitors.
Tian, Ye; He, Xiaofang; Li, Ruping; Wu, Yanxin; Ren, Qiang; Hou, Yusen.
Afiliación
  • Tian Y; School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
  • He X; School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
  • Li R; School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
  • Wu Y; School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
  • Ren Q; Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. Electronic address: renqiang@cdutcm.edu.cn.
  • Hou Y; School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China; State Key Laboratory of Southwestern Chinese Medicine Resources, College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. Electronic address: houyusen@cdutcm.edu.cn.
Bioorg Med Chem ; 112: 117874, 2024 Oct 01.
Article en En | MEDLINE | ID: mdl-39167977
ABSTRACT
Gout is an autoinflammatory disorder characterized by the accumulation of monosodium urate crystals in joints and other tissues, representing the predominant type of inflammatory arthritis with a notable prevalence and propensity for severe outcomes. The NLRP3 inflammasome, a member of the pyrin domain-containing NOD-like receptor family, exerts a substantial impact on both innate and adaptive immune responses and serves as a pivotal factor in the pathogenesis of gout. In recent years, there has been significant academic and industrial interest in the development of NLRP3-targeted small molecule inhibitors as a promising therapeutic approach for gout. To assess the advancements in NLRP3 inflammasome inhibitors for gout treatment, this review offers a comprehensive analysis and evaluation of current clinical candidates and other inhibitors targeting NLRP3 inflammasome from a chemical structure standpoint, with the goal of identifying more efficacious options for clinical management of gout.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inflamasomas / Proteína con Dominio Pirina 3 de la Familia NLR / Gota Límite: Animals / Humans Idioma: En Revista: Bioorg Med Chem Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inflamasomas / Proteína con Dominio Pirina 3 de la Familia NLR / Gota Límite: Animals / Humans Idioma: En Revista: Bioorg Med Chem Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido